CA
NZ
UK
AU
IND
US
Eloxx Pharmaceuticals (NASDAQ:ELOX) closed at $17.43 on Friday 31 July 2026, up 31.05%, having traded between $13.79 and $18.42.Volumewas 52,688 shares. The previous session had already added 8.66%, taking the two-day gain to 42.4%.
Alvotech (Nasdaq:ALVO) closed at $4.12 on Friday 31 July 2026, up 15.41% from $3.57. Nothing was announced that day. The development driving the move was disclosed two sessions earlier: a Form 6-K filed on 29 July reporting that the Food and Drug Administration had …
Moleculin Biotech (Nasdaq:MBRX) announced the pricing of a best-efforts public offering of an aggregate of 12,376,667 shares of common stock, or pre-funded warrants in lieu thereof, along with warrants to purchase up to 37,130,001 shares of common stock, at a combined public offering price …
Moleculin Biotech (Nasdaq:MBRX) announced updated preliminary blinded results from Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia. With 62 subjects evaluable to date, the preliminary blinded complete remission rate was …
60 Degrees Pharmaceuticals (NASDAQ:SXTP), a company focused on developing and commercializing medicines for vector-borne disease, has entered definitive agreements for a private placement priced at the market under Nasdaq rules. The offering consists of approximately 574,713 shares of common stock, or pre-funded warrants in …
Stryker (NYSE:SYK) shares are sliding roughly 6% today as investors react to second-quarter results reported Thursday evening that beat on adjusted EPS but showed revenue merely in line with consensus. Stryker, headquartered in Portage, Michigan, is a leading global medical technology company operating through …
CareDx, Inc. (NASDAQ:CDNA) shares are extending their rally today, building on Thursday's surge after the company posted blowout second-quarter 2026 results, with revenue jumping 52% year-over-year to $132 million, well above the $113.8 million consensus, and adjusted EPS of $0.37 crushing the $0.23 estimate. …
Novo Nordisk A/S (NYSE:NVO) shares are sinking today after the company announced that its Phase 3 ZEUS cardiovascular outcomes trial for ziltivekimab failed to meet its primary endpoint, showing no reduction in major adverse cardiovascular events versus placebo in people with atherosclerotic cardiovascular disease, …
DexCom, Inc. (NASDAQ:DXCM) shares are surging near 52-week highs today, up roughly 12%, after the company reported strong second-quarter 2026 results with revenue of $1.31 billion, up 13% year-over-year, beating estimates, and adjusted EPS of $0.70 topping the $0.61 consensus by 15%. DexCom, headquartered …
Replimune Group, Inc. (NASDAQ:REPL) shares are more than doubling today after the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 that efficacy results from the company's IGNYTE study for RP1 (vusolimogene oderparepvec) are evaluable and clinically meaningful. Replimune, headquartered in Woburn, Massachusetts …
Please wait processing your request...